Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 350

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 350
---
 We believe that Rewell will be at the forefront of wellness and prevention, enabling consumers to obtain personalized genetics and gut microbiome information, with nutrition recommendations and habit plans that support informed life changes that would mitigate disease initiation and development and improve overall wellbeing. Rewell’s proprietary platform provides personalized DNA and microbiome results by integrating customer’s genetic and lifestyle data and associated risk factors and comparing these results to both a standard and proprietary database. This aims at lowering the chances of developing low grade chronic inflammation over time, as Rewell provides insights from personal genomic information and their impact on and long -termhabits. According to public research, diets and environmental factors have a greater influence on the human gut microbiome than host genetics. Given these results, to provide accurate and relevant insights that account for geographical influences, we based the gut microbiome results provided by Rewell on a proprietary database constructed through patient trials tailored to the geography where the services are offered. This reference dataset was constructed through a citizen science initiative conducted from December 2015 to December 2016, which recruited 200 volunteers from various rural and urban areas in Argentina. Participants were instructed on the project’s objectives and directed to clinical labs in four partner cities for sample collection and informed consent. Following stringent inclusion criteria, 172 volunteers were included in the study, resulting in 516 biological samples analyzed for biochemical, metabolome, and microbiome data. Epidemiological and contextual metadata — including diet, clinical, and medication history — were collected to enhance analysis accuracy. Rewell’s platform leverages this comprehensive reference data to provide scientifically precise results, enabling users to manage their long -termhealth. This precision extends to detecting dysbiosis or imbalances in specific microbiome parameters by comparing customer samples against our reference dataset. Pilot tests have validated the platform’s effectiveness in accurately identifying microbiome variations, supporting users in making informed wellness decision. Currently, we have constructed a reference dataset only in Argentina, the sole market where Rewell is currently offered. To expand Rewell into new markets, we are actively building region -specificreference datasets. In Mexico, we have collected 80 biological samples to date, and we plan to continue gathering samples from various regions of the country to create a robust dataset tailored to the Mexican market. This process will be replicated in each new market where we plan to launch Rewell, ensuring that our platform provides insights aligned with the unique microbiome profiles of each region. Personal DNA and Gut Microbiome Profiling Rewell’s platform provides customers with direct access to their DNA and gut microbi